Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prostatype Genomics AB's change in working capital for the quarter that ended in Jun. 2026 was kr1.46 Mil.
Prostatype Genomics AB's change in working capital for the fiscal year that ended in Dec. 2025 was kr12.98 Mil.
It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).
Prostatype Genomics AB Change In Working Capital Related Terms
Prostatype Genomics AB Change In Working Capital Historical Data
* Premium members only.
The historical data trend for Prostatype Genomics AB's Change In Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB Change In Working Capital Chart
Prostatype Genomics AB Change In Working Capital Calculation
Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr12.55 Mil.
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.
Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net
(566)
(614)
(796)
Inventories
(1,667)
(2,759)
(3,727)
Accounts payable
531
1,061
2,687
Accrued liabilities
103
271
(935)
Accrued income taxes
(1,224)
981
994
For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Working Capital of kr12.55 Mil mean?
Prostatype Genomics AB (OSTO:PROGEN) has a Change In Working Capital of kr12.55 Mil as of Jun. 2026. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for Prostatype Genomics AB.
Is Prostatype Genomics AB's Change In Working Capital too high?
Prostatype Genomics AB's current Change In Working Capital is kr12.55 Mil. Overall, Prostatype Genomics AB has a GF Score™ of 12/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Change In Working Capital compare to TMO and DHR?
Prostatype Genomics AB's Change In Working Capital of kr12.55 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Working Capital for a Medical Diagnostics & Research company?
A good Change In Working Capital depends on the Medical Diagnostics & Research industry context. However, Change In Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Working Capital mean?
A high Change In Working Capital can signal that a stock is expensive relative to its fundamentals. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for Prostatype Genomics AB. Prostatype Genomics AB's current Change In Working Capital is kr12.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Fairly Valued. The stock's GF Value™ is kr0.15, compared to a current price of kr0.16 — trading 4% above its estimated fair value. The current Change In Working Capital is kr12.55 Mil. Prostatype Genomics AB's overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Working Capital calculated?
Change In Working Capital is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Change In Working Capital is kr12.55 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.16 is trading 4% above its estimated GF Value™ of kr0.15.
GuruFocus considers Prostatype Genomics AB to be Fairly Valued.
Key valuation signals for OSTO:PROGEN:
Change In Working Capital: kr12.55 Mil
GF Value™: kr0.15 vs. price of kr0.16 (4% above fair value)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
12GF Score
Get the complete analysis for OSTO:PROGEN
Change In Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
